Table 1.
Characteristics of Alpha and Delta variant COVID-19 cases.
| Variant | Alpha (B.1.1.7) | Delta (B.1.617.2) |
|---|---|---|
| N | 138 | 3637 |
| Age: | ||
| Median (IQR) | 26 (20–35) | 26 (21–35) |
| Mean (SD) | 28.7 (12.5) | 28.9 (13.3) |
| Male: N (%) | 74 (53.6%) | 1858 (51.1%) |
| Symptomatic patients: | ||
| -No | 82 (59.4%) | 1334 (36.7%) |
| -Yes | 56 (40.6%) | 2303 (63.3%) |
| Symptom onset/diagnosis time, N (%) | ||
| -1 day | 11 (19.6%) | 740 (32.1%) |
| -2–4 days | 28 (50%) | 1111 (48.2%) |
| -5–7 days | 12 (21.4%) | 367 (15.9%) |
| -8–14 days | 3 (5.4%) | 69 (3%) |
| ->14 days | 2 (3.6%) | 16 (0.7%) |
| Vaccination status: N (%) | ||
| -Unvaccinated | 102 (73.9%) | 2517 (69.2%) |
| -Incomplete vaccination (1 dose) | 23 (16.7%) | 613 (16.8%) |
| -Pfizer | 22 | 582 |
| -Moderna | 1 | 20 |
| -AstraZeneca | 0 | 7 |
| -Unknown | 0 | 4 |
| -Fully vaccinated (2 doses) | 13 (9.4%) | 507 (13.9%) |
| -Pfizer | 13 | 428 |
| -Moderna | -- | 30 |
| -AstraZeneca | -- | 21 |
| -AstraZeneca/Pfizer | -- | 7 |
| -Jansen (1 dose) | -- | 19 |
| -Unknown | -- | 2 |
| Nasopharyngeal viral load | ||
| (log10 copies/mL) | ||
| Median (IQR) | 6.2 (4.6–7.3) | 7 (5.7–7.8) |